Peptide-drug conjugates (PDCs): a novel trend of research and development on targeted therapy, hype or hope?

ABSTRACT: Peptide-drug conjugates (PDCs) are the next generation of targeted therapeutics drug after antibody-drug conjugates (ADCs), with the core benefits of enhanced cellular permeability and improved drug selectivity. Two drugs are now approved for market by US Food and Drug Administration (FDA), and in the last two years, the pharmaceutical companies have been developing PDCs as targeted therapeutic candidates for cancer, coronavirus disease 2019 (COVID-19), metabolic diseases, and so on. The therapeutic benefits of PDCs are significant, but poor stability, low bioactivity, long research and development time, and slow clinical development process as therapeutic agents of PDC, how can we design PDCs more effectively and what is the future direction of PDCs? This review summarises the components

SUBMITTER: Fu C 

PROVIDER: S-EPMC9978859 | biostudies-literature | 2023 Feb

REPOSITORIES: biostudies-literature